539 results on '"Behre, Gerhard"'
Search Results
152. Downregulation of c-Jun Expression by Transcription Factor C/EBPα Is Critical for Granulocytic Lineage Commitment
153. Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia
154. Ras Signaling Enhances the Activity of C/EBPα to Induce Granulocytic Differentiation by Phosphorylation of Serine 248
155. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
156. Adsorption von Pflanzenschutzmitteln und DOC an Saugkerzen aus Glas und Keramik
157. Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
158. Analysis of the Modulation of Transcriptional Activity in Myelopoiesis and Leukemogenesis
159. c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor
160. Use of a Promoterless Renilla Luciferase Vector as an Internal Control Plasmid for Transient Co-Transfection Assays of Ras-Mediated Transcription Activation
161. Proteomic identification of E6 AP as a molecular target of tamoxifen in MCF7 cells.
162. Proteomic approaches in myeloid leukemia.
163. Human herpesvirus-6 as an inducer of porphyria cutanea tarda: implications from a case.
164. AML1?ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia.
165. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML‐RARα in APL
166. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations
167. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia
168. Chromatin modifications induced by PML-RARα repress critical targets in leukemogenesis as analyzed by ChIP-Chip
169. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate
170. Heterozygous PU.1 mutations are associated with acute myeloid leukemia
171. Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions
172. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five cases.
173. Use of a Promoterless RenillaLuciferase Vector as an Internal Control Plasmid for Transient Co-Transfection Assays of Ras-Mediated Transcription Activation
174. Cytogenetics detects infiltrations of a primary cutaneous acute myeloid leukemia to the kidney.
175. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia<FNR HREF="fn1"></FNR><FN ID="fn1"> Presented at the Annual Congress of the German Society for Hematology and Oncology, Düsseldorf, Germany, 1996 (Kern W, Behre G, Büchner Th, Hiddemann W, for the German AML Cooperative Group. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myeloid leukemia: a phase III multicenter study. Ann Hematol 1996;73[Suppl 2]:A10). </FN>
176. Author Correction: Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement
177. Frequency of PU.1 mutations in acute myeloid leukemia
178. Correction to: EVI2B is a C/EBPαtarget gene required for granulocytic differentiation and functionality of hematopoietic progenitors
179. Prediction of Hepatic Complications after Allogeneic Haemotopoetic Stem Cell Transplantation Using Liver and Spleen Stiffness Measurement
180. MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance.
181. MiR-143 Targets ERK5 in Granulopoiesis and Predicts Outcome of Patients with Acute Myeloid Leukemia
182. High Expression of the DNMT3AEmbedded Pri- Mir -1301Associates with Improved Outcome in Patients with Acute Myeloid Leukemia
183. Reduction of Immunosuppression after Disease-Specific Donor Cell Chimerism Decrease Can Prevent Hematological Relapse Following Allogeneic Stem Cell Transplantation after Non-Myeloablative (NMA) Conditioning — Results of a Prospective Phase II Study. Eudract #: 2007-002420-15
184. In AML RASpathway Mutations Confer Worse Outcome in IDH1and IDH2Mutated AML Patients Receiving Hematopoietic Stem Cell Transplantation
185. Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
186. Absolute Quantification of Pre-microRNA-155Copy Numbers By Digital Droplet PCR Identifies Acute Myeloid Leukemia (AML) Patients with Adverse Outcome
187. Biological Associations and Clinical Impact of Differential Expression of the Pre-Mir-29a/b-1and Pre-Mir-29b-2/CClusters in Acute Myeloid Leukemia
188. High Expression of ZBTB7Aat Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving Hematopoietic Stem Cell Transplantation
189. High Blood BAALCCopy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia
190. Assessment of NPM1Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation
191. Prognostic Impact of Aberrant RUNX1Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
192. High Expression of the Hedgehog Transcription Factor GLI1Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning
193. Prognostic Implications of Pri-Mir-320aExpression in Acute Myeloid Leukemia Patients
194. High Pri-Mir-181a-1and Pri-Mir-181a-2Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning
195. High Expression of Mir-9down-Regulates the Poor Outcome Prognosticator ERG and Associates with Reduced Relapse-Rates in Acute Myeloid Leukemia
196. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.
197. Parvovirus B19 infection as trigger of graft vs. host disease.
198. Prognostic Significance Of EVI1expression In Acute Myeloid Leukemia Patients With Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic Hematopoietic Cell Transplantation With Reduced-Intensity Conditioning
199. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
200. Significant Role of Peptidyl-Prolyl cis/transIsomerase, Pin1 in Acute Myeloid Leukemia with C/EBPα Mutations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.